Quick answer
Cagrilintide is a lipidated, disulfide-cyclized, C-terminally amidated amylin analog of roughly 4.4 kDa; a credible lot needs both an HPLC trace and a mass-spectrometry identity check.
- Identity: theoretical average mass about 4,409 Da, observed as a series of multiply charged ions
- Three features to confirm: the C20 fatty diacid with its linker, the disulfide-stabilized ring, and the C-terminal amide
- HPLC: a late-eluting, hydrophobic main peak; non-acylated backbone elutes much earlier
- Beyond HPLC: area-percent purity is not net peptide content; aggregation and salt/water content need separate attention
- Listed purity: the cagrilintide research vial is listed at ≥98% HPLC; lot records are on the CoA page
- Research use: For laboratory research use only; not for human consumption.
Why cagrilintide needs more than a purity number
For laboratory research use only; not for human consumption.
Cagrilintide combines a modified amylin backbone with an acyl chain and a disulfide-stabilized ring. At roughly 4.4 kDa, with a C20 fatty diacid attached through a linker and a C-terminal amide, it is one of the more structurally demanding peptides in a typical research catalog, and its analysis reflects that complexity. A short, linear, unmodified peptide can often be judged from a single chromatogram and a single mass. A lipidated, cyclic peptide cannot, because several different things can go wrong during synthesis and conjugation while the headline purity still looks respectable.
Lot-level analytical testing exists to confirm that all three engineered features are correctly present: the lipid chain, the ring, and the amide terminus. This guide explains what each test measures, what the common failure signatures look like, and how to read a cagrilintide certificate of analysis (CoA) critically. For the compound's background and receptor pharmacology, see the cagrilintide research overview.
| Structural feature | What it contributes | Primary test that confirms it |
|---|---|---|
| C20 fatty diacid plus linker on a side chain | Extended duration through albumin-binding behavior in the engineered design | Mass spectrometry (mass of the intact molecule) and HPLC retention |
| Disulfide-stabilized ring | Conformation of the N-terminal region that the amylin-family scaffold relies on | Mass spectrometry (about 2 Da lower than the reduced form) |
| C-terminal amide | Neutral C-terminus typical of amylin-family peptides | Mass spectrometry (about 1 Da difference from the free acid) |
| Full-length sequence | Correct receptor-binding surface | Mass spectrometry; peptide mapping or MS/MS where sequence confirmation is needed |
Reversed-phase HPLC
HPLC separates the fully acylated, correctly cyclized peptide from incompletely conjugated or unmodified intermediates, with purity read per understanding HPLC purity. The acyl-chain conjugation in particular can produce a distinct impurity profile compared with unmodified peptides.
The lipid chain makes cagrilintide considerably more hydrophobic than an unmodified peptide of the same length, so it elutes late in a reversed-phase gradient and often needs a higher organic fraction or a wider-pore column for good peak shape. Shorter-chain stationary phases (C4 or C8 rather than C18) and a raised column temperature are common choices for lipidated peptides because they reduce on-column adsorption and peak broadening. Non-acylated backbone, by contrast, elutes much earlier, which makes it straightforward to spot.
Reading the cagrilintide chromatogram
The headline number on a cagrilintide report comes from integrating the chromatogram: main-peak area as a share of total peak area, measured by UV absorbance near 214–220 nm. Because it is a relative measure, it is only as good as the separation behind it. Reviewers typically check four things:
- The gradient is slow enough to pull near-identical species apart.
- The main peak is sharp and symmetrical, without fronting, tailing or a shoulder that suggests a co-eluting species.
- The baseline returns to zero between peaks.
- Small peaks are integrated and reported individually rather than omitted.
A chromatogram supplied without its method conditions is much harder to compare against a later re-test of the same lot. Column chemistry, mobile phases, gradient slope, temperature and wavelength should all be on the report.
Mass spectrometry for identity
Mass spectrometry confirms the molecule's mass matches the fully modified sequence described in its chemistry article, distinguishing it from partially acylated byproducts or the unmodified peptide backbone — see HPLC vs. mass spectrometry.
The theoretical average mass is approximately 4409 Da, observed as a series of multiply charged ions that the instrument software deconvolutes to a single neutral mass. Useful diagnostic differences include the mass of the missing acyl-linker unit, a 2 Da increase when the disulfide is not formed, and a 1 Da shift if the C-terminus is a free acid instead of an amide. A 1 Da difference is small against a 4.4 kDa parent, so it is only resolvable on an instrument with adequate resolution and accurate calibration; the CoA should state the instrument class and report observed and theoretical values side by side.
| Observation | Likely meaning | Where it shows up |
|---|---|---|
| Early-eluting peak, mass lower by the acyl-linker unit | Non-acylated backbone (incomplete conjugation) | HPLC and MS |
| Main-peak mass about 2 Da higher than expected | Disulfide not formed (reduced thiols) | MS |
| Main-peak mass about 1 Da different | Free-acid C-terminus instead of amide, or deamidation | MS (high resolution needed) |
| Broad late-eluting hump or very early void-volume material | Aggregates or poorly soluble material | HPLC, ideally confirmed by size-exclusion |
| Shoulder on the main peak with identical mass | Diastereomer or positional isomer | HPLC only; MS cannot distinguish |
Why this matters for a long-acting analog
Cagrilintide's research value as an extended-duration amylin-receptor agonist, detailed in its mechanism of action, depends specifically on the acyl-chain modification being intact; a lot with incomplete conjugation would behave more like a shorter-acting, less-engineered amylin analog and confound duration-focused comparisons, including against paired incretin compounds like semaglutide. The same logic applies to comparisons with the older, unlipidated analog discussed in cagrilintide vs. pramlintide: the comparison only means something if the cagrilintide in the assay really carries its lipid.
Aggregation is a further consideration. Amylin-family peptides are known for forming fibrils, and although cagrilintide is engineered to resist this, high-molecular-weight species are worth excluding before a duration-focused or receptor-potency experiment is interpreted. Size-exclusion chromatography is the usual orthogonal check, because aggregates may be lost on a reversed-phase column or elute as unresolved material.
What an HPLC percentage leaves out
Area-percent purity says how much of the peptide material is the intended sequence; it does not say how much of the powder is peptide. Counter-ions such as acetate or trifluoroacetate and bound water add mass without absorbing at the detection wavelength. Where assay concentrations need to be exact, net peptide content is the relevant figure, typically established by amino acid analysis or a quantitative nitrogen method, and the peptide calculator helps convert vial contents and diluent volume into a working concentration.
Three quantities are easy to conflate:
- HPLC purity — the main peak's share of UV-absorbing material.
- Net peptide content — the fraction of the dry powder that is peptide rather than salts and water.
- Identity — whether the main peak is actually the intended molecule, which only mass (and for sequence-level questions, fragmentation) can show.
A lot can score well on the first and still be mislabeled on the second or third. That is why a report with only a typed percentage is weak evidence, and why the product page for the 10 mg cagrilintide vial points to batch records rather than relying on the headline figure.
Documentation to expect
A lot-specific certificate of analysis with HPLC purity and mass-spec identity confirmation — see how to read a CoA. When checking a cagrilintide certificate, confirm that it carries:
- A batch identifier that matches the vial in hand
- An HPLC trace, not just a typed percentage, with method conditions
- Observed and expected mass values from the mass-spec run
- The analysis date and the testing laboratory's details
Independent verification adds a further layer; third-party testing explained covers what it does and does not prove. Batch records can be looked up on the CoA page. The store's own listing describes the vial as lyophilized powder with a sealed clear glass container and states that the sequence or identity is reported on the certificate of analysis where published, so the certificate, not the product description, is the document that settles identity questions.
Keeping a verified lot verified
Analytical results are a snapshot. Once a vial of cagrilintide is opened, humidity, temperature swings, and light exposure begin to matter, and a solution is less stable than the lyophilized cake it came from. The product page gives the supplied storage guidance: refrigerate at 2–8 °C, or at −20 °C for long-term storage, and protect the material from heat, moisture and light. After reconstitution, aliquot to avoid freeze-thaw cycling and note preparation dates so that any unexpected assay behavior can be traced back to material age; the general principles are in storing research peptides.
A practical habit is to retain a small, sealed, labeled aliquot from the lot at receipt. If an assay later drifts, that retained material can be re-run alongside the suspect working solution, which separates a degradation problem from a lot problem without guesswork.
Frequently asked questions
What mass should a cagrilintide CoA report?
An observed mass consistent with roughly 4409 Da for the fully acylated, cyclized, amidated molecule. The certificate should show theoretical and measured values together, along with the instrument used.
How would incomplete acylation show up?
As an earlier-eluting HPLC peak, because the unmodified backbone is less hydrophobic, and as a lower mass in the spectrum corresponding to loss of the fatty diacid and linker.
Is HPLC purity enough for a lipidated peptide?
It is necessary but not sufficient. Because several partially modified intermediates are possible, mass confirmation of the main peak is what establishes that the dominant species is the intended analog.
How can a lab tell whether the disulfide formed?
By mass. The ring-closed molecule is about 2 Da lighter than the reduced form with two free thiols. This needs an instrument with enough accuracy to resolve a 2 Da shift on a 4.4 kDa molecule.
Why does cagrilintide elute so late on reversed-phase HPLC?
The C20 fatty diacid is strongly hydrophobic, so the lipidated peptide binds the stationary phase more tightly than an unmodified peptide of similar length and needs a higher organic fraction to elute.
Does a ≥98% purity claim tell me how much peptide is in the vial?
No. Purity is a ratio of UV-absorbing species. The mass of peptide in the vial also depends on counter-ions and water, which is why net peptide content matters for exact concentrations.
Where can I check the record for the lot I received?
Use the CoA page and match the batch identifier on the vial to the report. If the identifiers do not match, regard the document as unverified for that vial.
Research Use Only. For laboratory research use only; not for human consumption. Supplied strictly for laboratory research and development, not for human or veterinary use, and not for diagnostic purposes. This article is research education, not usage guidance.
References
- Cagrilintide research overview (V8 Peptides)
- Understanding HPLC purity (V8 Peptides)
- HPLC vs. mass spectrometry (V8 Peptides)
- How to read a CoA (V8 Peptides)
- Cagrilintide product specification (V8 Peptides)